BLU Share Price Performance
CA$0
0.00 (0.00%)
Sorry, there is currently no price data for this company.
BLU Community Narratives
There are no narratives available yet.
Recent BLU News & Updates
No updates
BELLUS Health Inc. Key Details
Last Reported Earnings
Mar 31, 2023
Next Reporting Earnings
n/a
- Earnings per share (EPS)
- -0.68
- Gross Margin
- 100.00%
- Net Profit Margin
- -578,586.67%
- Debt/Equity Ratio
- 0%
BELLUS Health Inc. Competitors
About BLU
- Founded
- 1993
- Employees
- 74
- CEO
- WebsiteView website
BELLUS Health Inc., a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of refractory chronic cough (RCC) and other cough hypersensitivity indications. Its lead product candidate includes BLU-5937, an antagonist of the P2X3 receptor, which is in Phase II clinical trial for treatment of RCC and chronic pruritus. BELLUS Health Inc. was incorporated in 1993 and is based in Laval, Canada.
Canadian Market Performance
- 7 Days: -1.4%
- 3 Months: 8.0%
- 1 Year: 18.6%
- Year to Date: 8.7%
Over the last 7 days, the market has dropped 1.4%, driven by a loss of 2.1% in the Financials sector. As for the longer term, the market has actually risen by 19% in the last year. As for the next few years, earnings are expected to grow by 11% per annum. Market details ›
This week, we’re diving deeper into the world of agentic AI. We’re zeroing in on the core technologies that make these intelligent agents actually reliably work. We explore what all this could mean for software, start-ups, and most importantly, the opportunities and risks each industry faces by adopting Agentic AI.
Continue reading